{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:05:13Z","timestamp":1790521513233,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.bcp.2019.113669","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:46:03Z","timestamp":1571255163000},"page":"113669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity"],"prefix":"10.1016","volume":"170","author":[{"given":"Yanan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingkai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-9192","authenticated-orcid":false,"given":"Shansen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.113669_b0005","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","author":"Romoli","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2019.113669_b0010","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bcp.2019.113669_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial","volume":"97","author":"Atmaca","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2019.113669_b0020","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bcp.2019.113669_b0025","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0090-9556(25)08858-0","article-title":"Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid","volume":"14","author":"Rettenmeier","year":"1986","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2019.113669_b0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/cc3742","article-title":"Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?","volume":"9","author":"Lheureux","year":"2005","journal-title":"Critical care (London, England)."},{"key":"10.1016\/j.bcp.2019.113669_b0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/abio.2000.4947","article-title":"Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites","volume":"290","author":"Silva","year":"2001","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bcp.2019.113669_b0040","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bcpt.13049","article-title":"Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy","volume":"123","author":"Zhu","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2019.113669_b0045","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881117715608","article-title":"Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid","volume":"31","author":"Akgun","year":"2017","journal-title":"J. Psychopharmacol. (Oxford, England)."},{"key":"10.1016\/j.bcp.2019.113669_b0050","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/386186","article-title":"The need for biomarkers in diagnosis and prognosis of drug-induced liver disease: does metabolomics have any role?","volume":"2015","author":"Iruzubieta","year":"2015","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bcp.2019.113669_b0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jchromb.2014.08.011","article-title":"An effective assessment of valproate sodium-induced hepatotoxicity with UPLC-MS and (1)HNMR-based metabonomics approach","volume":"969","author":"Huo","year":"2014","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.bcp.2019.113669_b0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.toxlet.2017.12.015","article-title":"Metabolomics profiling of steatosis progression in HepaRG((R)) cells using sodium valproate","volume":"286","author":"Cuykx","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2019.113669_b0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/aps.2013.135","article-title":"Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats","volume":"35","author":"Zhang","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2019.113669_b0070","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"issue":"1679\u201394","key":"10.1016\/j.bcp.2019.113669_b0075","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Chavez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2019.113669_b0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mam.2017.06.001","article-title":"Mechanisms of bile acid mediated inflammation in the liver","volume":"56","author":"Li","year":"2017","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bcp.2019.113669_b0085","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2019.113669_b0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.phymed.2016.12.006","article-title":"Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor","volume":"25","author":"Duan","year":"2017","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2019.113669_b0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ebiom.2018.08.015","article-title":"Bile acid metabolites in early pregnancy and risk of gestational diabetes in Chinese women: a nested case-control study","volume":"35","author":"Li","year":"2018","journal-title":"EBioMedicine."},{"key":"10.1016\/j.bcp.2019.113669_b0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clinre.2015.12.017","article-title":"Bile acids in drug induced liver injury: Key players and surrogate markers","volume":"40","author":"Schadt","year":"2016","journal-title":"Clinics Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.bcp.2019.113669_b0105","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.bcp.2019.113669_b0110","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.bbrc.2017.11.201","article-title":"Impaired vagus function in rats suppresses bile acid synthesis in the liver by disrupting tight junctions and activating Fxr-Fgf15 signaling in the intestine","volume":"495","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2019.113669_b0115","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/clinchem\/47.7.1190","article-title":"Accumulation of free 3-hydroxy fatty acids in the culture media of fibroblasts from patients deficient in long-chain l-3-hydroxyacyl-CoA dehydrogenase: a useful diagnostic aid","volume":"47","author":"Jones","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bcp.2019.113669_b0120","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/clpt.2011.47","article-title":"Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study","volume":"89","author":"Price","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2019.113669_b0125","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.3390\/ijms160613004","article-title":"The N-Acetylglutamate synthase family: structures, function and mechanisms","volume":"16","author":"Shi","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2019.113669_b0130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hep.1840010411","article-title":"Choleretic effect of valproic acid in the rat","volume":"1","author":"Watkins","year":"1981","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.bcp.2019.113669_b0135","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/0024-3205(96)00422-5","article-title":"Ursodeoxycholate improves hepatobiliary dysfunction induced by valproate-carbamazepine treatment in the rat","volume":"59","author":"Mesdjian","year":"1996","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2019.113669_b0140","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.103.064220","article-title":"Abolition of valproate-derived choleresis in the Mrp2 transporter-deficient rat","volume":"310","author":"Wright","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.113669_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2017.05.009","article-title":"Quantitative targeted bile acid profiling as new markers for DILI in a model of methapyrilene-induced liver injury in rats","volume":"386","author":"Slopianka","year":"2017","journal-title":"Toxicology"},{"key":"10.1016\/j.bcp.2019.113669_b0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cbi.2015.08.016","article-title":"Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: Promising diagnostic biomarkers for cholestasis","volume":"255","author":"Masubuchi","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2019.113669_b0155","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MEG.0b013e3282f4710a","article-title":"Bile acid levels are increased in the liver of patients with steatohepatitis","volume":"20","author":"Aranha","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2019.113669_b0160","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/hep.20548","article-title":"Serum alanine aminotransferase in skeletal muscle diseases","volume":"41","author":"Nathwani","year":"2005","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.bcp.2019.113669_b0165","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3389\/fphar.2019.00819","article-title":"Lipidomic Profiling Reveals Disruption of Lipid Metabolism in Valproic Acid-Induced Hepatotoxicity","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2019.113669_b0170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-017-0479-z","article-title":"Dispensability of annual laboratory follow-up after more than 2 years of valproic acid use: a systematic review","volume":"31","author":"Meijboom","year":"2017","journal-title":"CNS drugs."},{"key":"10.1016\/j.bcp.2019.113669_b0175","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.20074","article-title":"Valproate therapy and nonalcoholic fatty liver disease","volume":"55","author":"Luef","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2019.113669_b0180","first-page":"1573","article-title":"Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models","volume":"88","author":"Vitins","year":"2014","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2019.113669_b0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.taap.2007.09.014","article-title":"Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver","volume":"226","author":"Lee","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2019.113669_b0190","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.bcp.2019.113669_b0195","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1124\/mol.114.096313","article-title":"Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease","volume":"87","author":"Benet","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2019.113669_b0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.tox.2017.11.013","article-title":"Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction","volume":"393","author":"van Breda","year":"2018","journal-title":"Toxicology"},{"key":"10.1016\/j.bcp.2019.113669_b0205","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bcp.2019.113669_b0210","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1172\/JCI88893","article-title":"Nutrient-sensing nuclear receptors PPARalpha and FXR control liver energy balance","volume":"127","author":"Preidis","year":"2017","journal-title":"J. Clin. Investig."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:07:01Z","timestamp":1757768821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219303685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":42,"alternative-id":["S0006295219303685"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113669","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113669"}}